The record
FDA's 2023 talc sampling assignment tested 50 samples and asbestos was detected in none of them.
Claim scope
50 samples, zero positives. Confirmed against the published summary table across all three parts: 53 result rows, 50 distinct base sample numbers (sample 04032023-14 was analyzed as four sub-samples 14.1-14.4), every row 'negative' for both PLM and TEM.
What this source does not establish
Does not establish market-wide absence. Does not extend past 2023 — see the finding on the absence of a published 2024/2025 survey.
Limitations
Row count (53) exceeds sample count (50) because of replicate sub-samples; do not report 53 samples. The 2023 selection criteria added 'products marketed to women of color'.
Source
Gov Report — FDA Constituent Update, April 5, 2024 — 'FDA Releases Data from the Agency's 2023 Testing of Talc-Containing Cosmetic Products for Asbestos'; data table 'FDA Summary of Results ... completed by AMA Laboratories in 2023' (Parts 1-3: 04032023-1..14, 04252023-1..17, 05162023-1..19)